Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Merus
(https://merus.nl) 📸 Data Snapshot: May 24, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Closing in on cancer | Merus (https://merus.nl)
Closing in on cancer | Merus
At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and…
NAV_HEADER_REPEATED_FOOTER About Us | Merus (https://merus.nl/about/)
About Us | Merus
At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.
NAV_HEADER_REPEATED_BODY Multiclonics® Platform | Merus (https://merus.nl/technology/multiclonics-platform/)
Multiclonics® Platform | Merus
Our Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains…
NAV_HEADER_REPEATED_FOOTER Pipeline | Merus (https://merus.nl/pipeline/)
Pipeline | Merus
You can find the latest information on our pipeline on the Genmab Pipeline page https://www.genmab.com/antibody-science/
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://merus.nl) Closing in on cancer | Merus
[H1] Closing in on Cancer [H2] Every Day. At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and developing new treatments for cancer. Multiclonics® Platform Clinical Trials Our Pipeline
SUB-PAGE (https://merus.nl/about/) About Us | Merus
[H1] Closing in on Cancer [H2] Every Day. Cancer is a devastating disease, but we’re up to the challenge and unwavering in our determination. Every day, we’re moving ahead in our mission to close in on cancer, by discovering and developing new medicines for patients. Our innovative multispecific Multiclonic® antibody therapeutics are engineered with compelling target combinations to work against the complex mechanisms that drive cancer. At the forefront of our pipeline is petosemtamab, a novel bispecific antibody being evaluated in two phase three registrational trials for head and neck cancer. [H2] Multispecific antibody platform Our Multiclonics® therapeutics are full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies that bind to multiple targets, and are manufactured with advantageous features for anti-cancer effects against the complex mechanisms that drive cancer. Multiclonics® are capable of being developed with industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Biclonics® can also be conjugated with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets with the potential for improved binding selectivity, internalization and cancer cell killing activity. [H2] Established clinical pipeline Our therapeutic candidates engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways by utilizing our proprietary technology platform and deep expertise in oncology. We are currently developing a broad pipeline of wholly owned and licensed Biclonics® drug candidates in the clinic with compelling target combinations and unique mechanisms of action. [H2] Lead asset petosemtamab Our lead cancer drug candidate is petosemtamab, a Biclonics® antibody targeting EGFR and LGR5. Petosemtamab has shown encouraging single agent clinical activity in previously treated, 2L+ recurrent or metastatic (r/m) head and neck cancer, and in combination with pembrolizumab in first line (1L) PD-L1+ r/m head and neck cancer, with phase three trials enrolling in both indications. An evaluation of petosemtamab monotherapy in 3L+ metastatic colorectal cancer (mCRC) and in combination with standard chemotherapy in 1L and 2L mCRC is ongoing.
SUB-PAGE (https://merus.nl/technology/multiclonics-platform/) Multiclonics® Platform | Merus
[H1] Merus Multiclonics® Our Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains against virtually any target. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies, using our Biclonics® and Triclonics® platforms. These platforms allow us to functionally evaluate our antibodies by generating large numbers of diverse panels of antibodies and to functionally screen them at high throughput to lead to the discovery of therapeutic candidates with unique and innovative properties. Further, by creating antibodies that bind to multiple targets, Biclonics® and Triclonics® may be designed to have a variety of mechanisms of action against cancer, including blocking tumor cell growth and survival and mobilizing a patient’s immune response to fight cancer. Biclonics® can also be conjugated with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets with the potential for improved binding selectivity, internalization and cancer cell killing activity. [H2] Distinctive Characteristics of Multiclonics® Deliver Unique Functionality [H2] Unique Functionality Our Multiclonics® have been shown to retain the qualities of natural human, full-length immunoglobulin G (IgG) antibodies, including stability, long half-life and low immunogenicity. Biclonics® are differentiated from many other bispecific antibody formats because they do not require linkers or modifications to force correct pairing of heavy and light chains nor do they require fusion proteins to add functionality. With the IgG format of natural antibodies, Biclonics® can be reliably manufactured with high yields. Triclonics® have a unique antibody design capable of simultaneously binding three targets at once. Triclonics® have the potential to enable tumor cell-killing activity and/or to modulate the immune system to promote more robust and specific anti-tumor immune responses. [H2] Multiclonics® Our Multiclonics® platforms provide patented means for efficient discovery, screening and identification of multispecific antibodies capable of differentiated biology having novel target combinations and activity. [H3] Biclonics® Biclonics® bispecific antibodies are capable of binding two different targets in cis for dual cancer cell targeting or trans for bridging the cancer cell to an immune effector cell. [H3] Triclonics® Triclonics® trispecific antibodies are capable of binding three different targets. [H3] ADClonics® The Biclonics® format and platform is compatible with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets for improved selectivity and potency. [H2] Multiclonics® Platforms Our platforms use unbiased high throughput functional screening in molecular and cell-based assays to identify novel, innovative Biclonics® and Triclonics® antibodies. Our lead molecules are selected from up to thousands of candidates generated from these platforms, identifying those molecules that possess unique biology and specific characteristics for therapeutic application. [H2] Scientific Publications To read more about Merus platform and its leading Biclonics® technology, please follow the link below for access to scientific publications. View Publications
SUB-PAGE · THIN (https://merus.nl/pipeline/) Pipeline | Merus
[H2] Merus is now part of Genmab. You can find the latest information on our pipeline on the Genmab Pipeline page https://www.genmab.com/antibody-science/pipeline
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /about/ | 2 | 0 |
| /technology/multiclonics-platform/ | 3 | 0 |
| /pipeline/ | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@id": "https://merus.nl/#/schema/Organization"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/",
"url": "https://merus.nl/",
"name": "Closing in on cancer | Merus",
"description": "At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and…",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": {
"@type": "ListItem",
"position": 1,
"name": "Merus"
}
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/"
},
"about": {
"@id": "https://merus.nl/#/schema/Organization"
}
},
{
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
]
}
/about/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/about/",
"url": "https://merus.nl/about/",
"name": "About Us | Merus",
"description": "At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": "https://merus.nl/",
"name": "Merus"
},
{
"@type": "ListItem",
"position": 2,
"name": "About Us"
}
]
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/about/"
}
}
]
}
/technology/multiclonics-platform/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/technology/multiclonics-platform/",
"url": "https://merus.nl/technology/multiclonics-platform/",
"name": "Multiclonics® Platform | Merus",
"description": "Our Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains…",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": "https://merus.nl/",
"name": "Merus"
},
{
"@type": "ListItem",
"position": 2,
"item": "https://merus.nl/technology/",
"name": "Technology"
},
{
"@type": "ListItem",
"position": 3,
"name": "Multiclonics® Platform"
}
]
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/technology/multiclonics-platform/"
}
}
]
}
/pipeline/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/pipeline/",
"url": "https://merus.nl/pipeline/",
"name": "Pipeline | Merus",
"description": "You can find the latest information on our pipeline on the Genmab Pipeline page https://www.genmab.com/antibody-science/",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": "https://merus.nl/",
"name": "Merus"
},
{
"@type": "ListItem",
"position": 2,
"name": "Pipeline"
}
]
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/pipeline/"
}
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 587 businesses audited.
Merus has 8.8 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Merus (merus.nl)
Merus is a high-substance biotech entity currently undergoing a ‘zombie site’ transition following its acquisition by Genmab. While its technical claims are granular and likely legitimate, the presence of consumer-style review schemas and the abandonment of its own pipeline tracking are significant BS indicators for an industry where precision and transparency are paramount.
Remove the review_count schema and any star-rating artifacts immediately to eliminate trust theatre signals. Update the homepage H1 and meta-description to reflect the Genmab acquisition to ensure semantic coherence. Replace the ‘Scientific Publications’ button with direct, numbered citations and outbound DOI links to clinical results. Add a ‘Leadership’ section with named experts and linked LinkedIn profiles or ORCID IDs to close the authority gap.
The site strongly aligns with the Pharma & Biotech industry, specifically clinical-stage oncology. The presence of specific drug candidates like petosemtamab and detailed descriptions of bispecific antibody platforms (Multiclonics) confirms this classification.
“The score of 32 is driven primarily by Trust and Proof deficiencies (Review counts vs Proof links) and the Semantic Drift caused by the Genmab acquisition disclosure being buried on a sub-page. The high technical specificity in the antibody descriptions prevents the score from reaching the 'Moderate BS' range.”
This training module utilizes a snapshot of public data from Merus, captured on May 24, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Merus: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://merus.nl to view the most current version of its content and learn from the source what this company is about and what it offers.